• Miscellaneous hematological agents

Mozobil Generic Name & Formulations

General Description

Plerixafor 20mg/mL; soln for SC inj; preservative-free.

Pharmacological Class

Hematopoietic stem cell mobilizer.

How Supplied

Single-dose vial (1.2mL)—1


Generic Availability


Mechanism of Action

Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans.

Mozobil Indications


In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.

Mozobil Dosage and Administration


Start after 4 days' treatment with G-CSF. Give by SC inj approx.11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. ≤83kg: 20mg fixed dose or 0.24mg/kg once daily; >83kg: 0.24mg/kg once daily. Max 40mg/day. Renal impairment (CrCl≤50mL/min): ≤83kg: 13mg or 0.16mg/kg once daily; >83–<160kg: 0.16mg/kg once daily; max 27mg/day.


Not established.

Mozobil Contraindications

Not Applicable

Mozobil Boxed Warnings

Not Applicable

Mozobil Warnings/Precautions


Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts. Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs of hypersensitivity during and after administration for at least 30mins. Have anaphylactic treatment readily available. Moderate to severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 week after last dose. Pregnancy: avoid; exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after last dose).

Mozobil Pharmacokinetics

See Literature

Mozobil Interactions


May be potentiated by drugs that reduce renal function or compete for active tubular secretion.

Mozobil Adverse Reactions

Adverse Reactions

Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; hypersensitivity reactions (may be serious), tumor cell mobilization, leukocytosis, thrombocytopenia, enlarged spleen, vasovagal reaction may occur.

Mozobil Clinical Trials

See Literature

Mozobil Note

Not Applicable

Mozobil Patient Counseling

See Literature